HMO drug formulary access increases for COX-2s.
D000068579:Celecoxib; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000600:supply & distribution* / Q000627:therapeutic use; D005569:Formularies as Topic; D006279:Health Maintenance Organizations / Q000458:organization & administration*; D006801:Humans; D007356:Insurance, Pharmaceutical Services; D007527:Isoenzymes / Q000187:drug effects; D007783:Lactones / Q000600:supply & distribution* / Q000627:therapeutic use; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases / Q000187:drug effects; D011720:Pyrazoles; D013449:Sulfonamides / Q000600:supply & distribution* / Q000627:therapeutic use; D013450:Sulfones; D014481:United States
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D007783:Lactones; D008565:Membrane Proteins; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D000068579:Celecoxib